Xin Zheng1, Shulin Chen1, Linfang Li1, Xiaohua Liu1, Xiaomin Liu1, Shuqin Dai1, Peng Zhang2, Huaiwu Lu3, Zhongqiu Lin3, Yuefei Yu4, Guorong Li5. 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China. 2. Guangzhou Hengtai Biotech Ltd, 11 Kaiyuan Road, Guangzhou, Guangdong 510530, China. 3. Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, China. 4. Guangzhou Hengtai Biotech Ltd, 11 Kaiyuan Road, Guangzhou, Guangdong 510530, China; Ameritech Biomedicines, Inc, 5106 Rainflower Cir N, League City, TX 77573, USA. Electronic address: yfyu1963@163.com. 5. Inserm U1059, Saint-Etienne 42023, France; CHU Saint-Etienne, Department of Urology/Plateau of Biology, 42055, France. Electronic address: grli2001@yahoo.fr.
Abstract
OBJECTIVE: Serum human epididymis protein 4 (HE4) and transthyretin (TTR) are new markers for ovarian cancer. We compared HE4 and TTR with the gold marker CA-125 for the diagnosis of ovarian cancer patients. METHODS: One hundred and thirty serum samples from benign ovarian tumor and 400 serum samples from healthy women were used to set up the cut-off. One hundred and twenty-six serum samples from ovarian cancer patients before operation were collected to test the diagnostic value of these ELISA assays. The sensitivity, positive predictive value (PPV) and ROC curves were used to evaluate the diagnostic value. RESULTS: For CA-125, the sensitivity and PPV were respectively 64.29% and 53.57% for stage I-II cancer patients, and respectively 91.43% and 88.57% for stage III-IV cancer patients. For HE4, the sensitivity and PPV were respectively 46.4% and 43.3% for stage I-II cancer patients, and respectively 88.6% and 49.2% for stage III-IV cancer patients. For TTR, the sensitivity and PPV were respectively 78.6% and 68.8% for stage I-II cancer patients, and respectively 82.9% and 74.3% for stage III-IV cancer patients. For CA125, the ROC was respectively 0.7941 and 0.9520 for stage I-II patients and stage III-IV patients. For HE4, the diagnostic value of ROC was 0.7071 for stage I-II cancer patients and 0.9250 for stage III-IV cancer patients. For TTR, the diagnostic value of ROC was 0.9112 for stage I-II cancer patients and 0.9322 for stage III-IV cancer patients. CONCLUSION: Our results support that TTR is an efficient serum marker for the diagnosis of early stage ovarian cancer patients.
OBJECTIVE: Serum human epididymis protein 4 (HE4) and transthyretin (TTR) are new markers for ovarian cancer. We compared HE4 and TTR with the gold marker CA-125 for the diagnosis of ovarian cancerpatients. METHODS: One hundred and thirty serum samples from benign ovarian tumor and 400 serum samples from healthy women were used to set up the cut-off. One hundred and twenty-six serum samples from ovarian cancerpatients before operation were collected to test the diagnostic value of these ELISA assays. The sensitivity, positive predictive value (PPV) and ROC curves were used to evaluate the diagnostic value. RESULTS: For CA-125, the sensitivity and PPV were respectively 64.29% and 53.57% for stage I-II cancerpatients, and respectively 91.43% and 88.57% for stage III-IV cancerpatients. For HE4, the sensitivity and PPV were respectively 46.4% and 43.3% for stage I-II cancerpatients, and respectively 88.6% and 49.2% for stage III-IV cancerpatients. For TTR, the sensitivity and PPV were respectively 78.6% and 68.8% for stage I-II cancerpatients, and respectively 82.9% and 74.3% for stage III-IV cancerpatients. For CA125, the ROC was respectively 0.7941 and 0.9520 for stage I-II patients and stage III-IV patients. For HE4, the diagnostic value of ROC was 0.7071 for stage I-II cancerpatients and 0.9250 for stage III-IV cancerpatients. For TTR, the diagnostic value of ROC was 0.9112 for stage I-II cancerpatients and 0.9322 for stage III-IV cancerpatients. CONCLUSION: Our results support that TTR is an efficient serum marker for the diagnosis of early stage ovarian cancerpatients.
Authors: Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-13 Impact factor: 4.254
Authors: Eda G Ramirez-Valles; Alicia Rodríguez-Pulido; Marcelo Barraza-Salas; Isaac Martínez-Velis; Iván Meneses-Morales; Víctor M Ayala-García; Carlos A Alba-Fierro Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec